Composition, methods for the treatment of neurodegenerative disease, dyskinesia, dystonia, myoclonus or tremors, psychosis, a neuropsychiatric disease, an unhealthy and migraine condition, compound, methods of inhibiting the activity of a monoamine receptor and activating a Monoamine receptor methods of identification of genetic polymorphism and an appropriate patient for treatment with the compound

摘要

"COMPOSITION, METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE, DYSKINESIA, MYOCLONIAS OR TERMS, PSYCHOSIS, OF A NEUROPSIQUIATRIC DISEASE, A CONDITION OF MONODY AND DISEASE AXOSIS OF COMPOSITION "A MONOAMINE RECEIVER, METHODS FOR IDENTIFYING GENETIC POLYMORPHISM AND A PATIENT SUITABLE FOR COMPOSITE TREATMENT". Behavioral pharmacological data with the innovative and selective 5HT2A / 2C receptor inverse agonist compound of formula (I) demonstrate efficacy in vivo in models of psychosis and dyskinesias. This includes activity in reversal of MK-801-induced locomotor behaviors, suggesting that this compound may be effective antipsychotic, and activity in MPTP dyskinesia primate model, suggesting efficacy as an antidyskinesia agent. These data support the hypothesis that 5HT2A / 2C receptor inverse agonism may confer antipsychotic and antidiskinetic efficacy in humans and indicate a use of the compound of formula (I) and related agents as innovative therapies for Parkinson's disease, neurodegenerative diseases. related human and psychosis.